Orchestra BioMed Holdings (OBIO) Liabilities and Shareholders Equity (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $100.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 70.46% year-over-year to $100.7 million; the TTM figure through Mar 2026 stood at $363.1 million (up 28.35% YoY), while the FY2025 annual figure was $114.9 million, up 50.78% from the prior year.
• Liabilities and Shareholders Equity eased to $100.7 million in Q1 2026 per OBIO's latest filing, from $114.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $161.6 million in Q2 2022 and bottomed at $42.8 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $99.4 million across 5 years, with a median of $95.6 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 57.59% — and 2026, when it soared 70.46%.
• Orchestra BioMed Holdings' Liabilities and Shareholders Equity stood at $95.6 million in 2022, then declined by 0.38% to $95.2 million in 2023, then dropped by 20.0% to $76.2 million in 2024, then jumped by 50.78% to $114.9 million in 2025, then decreased by 12.36% to $100.7 million in 2026.
• Business Quant data shows OBIO's Liabilities and Shareholders Equity at $100.7 million in Q1 2026, $114.9 million in Q4 2025, and $104.8 million in Q3 2025.